Everspin Technologies (MRAM) Faces A Board Exit And Earnings, Where Does Fair Value Sit?

Advertisement

Board resignation and upcoming earnings put Everspin Technologies (MRAM) in focus

Everspin Technologies (MRAM) has drawn investor attention after board member Lawrence G. Finch submitted his resignation, effective August 4, 2026. The announcement comes shortly before the company reports second quarter 2026 results on August 5.

See our latest analysis for Everspin Technologies.

Beyond the board change and upcoming results, Everspin Technologies’ recent trading has been volatile, with the 30-day share price return down 37.09% but the year-to-date share price return at 59.64% and the 1-year total shareholder return at 139.70%. This points to momentum that has cooled in the short term after strong gains.

If this kind of swing in sentiment has you looking wider than a single semiconductor stock, it could be a good moment to check out 54 AI infrastructure stocks

After a sharp pullback, and with a share price of $16.06 sitting well below the average analyst target of $24.67 and internal fair value estimates, where does a reasonable fair value range for Everspin Technologies actually sit now?

Most Popular Narrative: 34.9% Undervalued

On the most followed narrative, Everspin Technologies screens as undervalued, with a fair value of $24.67 set against the latest close at $16.06. That view rests on some ambitious growth and profitability assumptions.

Broader adoption of MRAM for data center and industrial automation driven by increasing demand for persistent, low-latency memory in AI, IoT, and edge computing is supporting sequential revenue growth and expanding Everspin's addressable markets, which can lead to sustained top-line revenue growth.

Read the complete narrative.

Want to see what underpins that upside view? The narrative leans heavily on faster revenue expansion, rising margins, and a future earnings multiple that assumes Everspin Technologies keeps executing.

Result: Fair Value of $24.67 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, there are still clear swing factors here, including execution risk around new MRAM product ramps and the possibility that key defense and government contracts do not renew on expected terms.

Find out about the key risks to this Everspin Technologies narrative.

Next Steps

With Everspin Technologies drawing mixed sentiment, do you want to rely on headlines or your own work? Take a closer look at the balance of upside and downside and weigh the 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond Everspin Technologies?

If Everspin Technologies has your attention, do not stop there. Widen your watchlist with a few focused stock ideas that match different investing styles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Everspin Technologies might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGM:MRAM

Everspin Technologies

Manufactures and sells magnetoresistive random access memory (MRAM) technologies in the United States, Japan, Hong Kong, Germany, Singapore, Canada, and internationally.

Flawless balance sheet and good value.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1158.7% undervalued
32 users have followed this narrative
2 users have commented on this narrative
6 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.6% undervalued
49 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9220.2% undervalued
14 users have followed this narrative
0 users have commented on this narrative
7 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$1908.3% undervalued
11 users have followed this narrative
0 users have commented on this narrative
7 users have liked this narrative

Updated Narratives

AV
IOT logo
Averagemike on Samsara ·

Samsara's Future PE Will Soar to 337.7x and the Future is Bright

Fair Value:US$57.34k99.9% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
JO
John_Eric
NOW logo
John_Eric on ServiceNow ·

The Company Nobody Brags About

Fair Value:US$266.0164.1% undervalued
30 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AN
AnimalDoctorKwon
A176750 logo
AnimalDoctorKwon on DuChemBIOLtd ·

DuChemBio absorbs Radio DNS Labs as Novartis injects 140B KRW into Korean RLT. With 100%+ OCF/EBITDA, the 6-mo lag is a de-risked steal.

Fair Value:₩10k43.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

IN
Investingwilly
MA logo
Investingwilly on Mastercard ·

Mastercard: The Best Dividend Stock You're Ignoring

Fair Value:US$75029.1% undervalued
102 users have followed this narrative
1 users have commented on this narrative
9 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6514.6% undervalued
69 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative
BL
BlackGoat
CBRS logo
BlackGoat on Cerebras Systems ·

The Wafer Giant Threatening NVIDIA's GPU Hegemony

Fair Value:US$415.5449.5% undervalued
64 users have followed this narrative
3 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

ST
StoxEurope
AD logo
StoxEurope on Koninklijke Ahold Delhaize ·

I ran Ahold Delhaize through a three-model triangulation — DCF, dividend discount, and residual income — with every assumption published and tagged as fact or assumption. The interesting result isn't a number, it's a disagreement: the point estimates run from €20,03 (RIM) through €27,64 (DDM) to €64,91 (DCF), and the pairwise overlaps form two disjoint segments — €20,36–€21,54 and €39,60–€44,56. Between €21,54 and €39,60, no two of the three models agree. [img]https://staticm.fastcomments.com/1784197249786-1000x1000-ad-range-strip.png[/img] Most of the spread is lens properties rather than company drama. A dividend model structurally can't see the roughly half of shareholder returns Ahold pays through buybacks. The book is ~96 % goodwill from the 2016 merger, which pins the residual-income reading low. And ~83 % of the DCF's value sits beyond the explicit five years, so it leans hard on the terminal assumptions. Three honest lenses, three honest answers — the disagreement is the information. Disclosures Position disclosure: The author holds no position in Ahold Delhaize as at 9 July 2026. This valuation is a StoxEurope opinion, based on honest research. Mistakes are possible. This is not investment advice. Do your own research. This article demonstrates a valuation methodology. It is not an investment recommendation, is not personalised to any reader's circumstances, and every figure in it depends entirely on the stated assumptions

1
|
0